[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. --------------------------------------------------------------- [707% Growth For American Lithium Company After They Fight Back Against China]( [They've Already Seen 707% Growth In 2021, And That Could Just Be The Start]( --------------------------------------------------------------- July 6, 2022 From the desk of the Editor (Five Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers of all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- ["The Most Critical Metal for Global Economies"]() The soaring demand for this "red rock" may be the most important development in 2022. It's key in the transition to the new green energy economies. Bloomberg News warns… "Within a decade, the world may face a massive shortfall of what's arguably the most critical metal for global economies." Copper prices have nearly doubled in the past year. [Find Out How This Is Good News for Commodity Investors.]() --------------------------------------------------------------- [Trevi Therapeutics, TRVI](=) Recent Analyst Action: Serge Belanger, analyst at Needham, reiterates coverage on [Trevi Therapeutics (TRVI)](in the Healthcare sector with a Buy rating and a price target of $10 (1 week ago). - Recent Price: $3.53 - Average Analyst Price Target: $10.00 (183.29%) - Market Cap: $129.21M [TipRanks.com]() also reports that [Trevi Therapeutics]()currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $10.00. The target pricing ranges from a high forecast of $10.00 down to a low forecast of $10.00. [Trevi Therapeutics (TRVI)]()’s last closing price was $3.53 which would put the average price target at $10.00. Here are 3rd party ratings for [TRVI](: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 31% (76 out of 251) [Click here for chart >>](=) -------------------------------------------------------------------------- --------------------------------------------------------------- [Fed Exposed! Former government insider tells ALL Secret plan to destroy the markets?]( This [former government insider]( just went on LIVE camera and exposed the Federal Reserve for what it REALLY is… An institution created in secret designed to rob you of your savings, and destroy your wealth. And even though we all know these central bankers have blood on their hands (inflation, the Greenspan bubble, Ben Bernanke)… No one, and I mean NO ONE expected [this](. If what this insider says is correct, you may only have days to prepare. [Click here to see his shocking exposé.]( --------------------------------------------------------------- [Beyond Air, XAIR](=) Recent Analyst Action: Scott Henry, analyst at Roth Capital, reiterates coverage on [Beyond Air (XAIR)](in the Technology sector with a Buy rating and a price target of $15 (6 days ago). - Recent Price: $9.61 - Average Analyst Price Target: $17.75 (84.70%) - Market Cap: $252.37M [TipRanks.com](=) also reports that [Beyond Air](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $17.75. The target pricing ranges from a high forecast of $23.00 down to a low forecast of $13.00. [Beyond Air (XAIR)](’s last closing price was $9.61 which would put the average price target at $17.75. Here are 3rd party ratings for [XAIR](=): - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 31% (76 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Atara Biotherapeutics, ATRA](=) Recent Analyst Action: Salim Syed, analyst at Mizuho Securities, reiterates coverage on [Atara Biotherapeutics (ATRA)](=)in the Healthcare sector with a Buy rating and a price target of $39 (1 week ago). - Recent Price: $9.08 - Average Analyst Price Target: $19.20 (111.45%) - Market Cap: $815.43M [TipRanks.com]() also reports that [Atara Biotherapeutics](=)currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $19.20. The target pricing ranges from a high forecast of $39.00 down to a low forecast of $4.00. [Atara Biotherapeutics (ATRA)](’s last closing price was $9.08 which would put the average price target at $19.20. Here are 3rd party ratings for [ATRA](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 31% (76 out of 251) [Click here for chart >>](=) -------------------------------------------------------------------------- --------------------------------------------------------------- [Revolutionary New "Infinity Chamber" Could Render Your Computer Obsolete!]( stunning breakthrough in quantum physics has unleashed a radical new technology that could render your computer obsolete, generating a potential $8 trillion in new wealth. Today, for the first time in history, investors can grab a ground-floor stake in this game-changing opportunity. [Go here now for the MUST-SEE VIDEO!]( --------------------------------------------------------------- [Olink Holding, OLK](=) Recent Analyst Action: Tejas Savant, analyst at Morgan Stanley, reiterates coverage on [Olink Holding (OLK)]()in the Healthcare sector with a Hold rating and a price target of $15 (1 month ago). - Recent Price: $18.04 - Average Analyst Price Target: $18.33 (1.61%) - Market Cap: $1.93B [TipRanks.com]( also reports that [Olink Holding](=)currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $18.33. The target pricing ranges from a high forecast of $20.00 down to a low forecast of $15.00. [Olink Holding (OLK)](=)’s last closing price was $18.04 which would put the average price target at $18.33. Here are 3rd party ratings for [OLK](=): - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Buy, Bottom 44% (139 out of 251) [Click here for chart >>]() -------------------------------------------------------------------------- [Revolution Medicines, RVMD]( Recent Analyst Action: Jonathan Chang, analyst at SVB Securities, reiterates coverage on [Revolution Medicines (RVMD)](in the Healthcare sector with a Buy rating (1 month ago). - Recent Price: $23.68 - Average Analyst Price Target: $29.67 (25.30%) - Market Cap: $1.72B [TipRanks.com](=) also reports that [Revolution Medicines]()currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $29.67. The target pricing ranges from a high forecast of $40.00 down to a low forecast of $24.00. [Revolution Medicines (RVMD)](’s last closing price was $23.68 which would put the average price target at $29.67. Here are 3rd party ratings for [RVMD](: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 37% (91 out of 251) [Click here for chart >>]() -------------------------------------------------------------------------- --------------------------------------------------------------- [Squeeze this "cash spout" for instant gas, grocery, rent money]() What if instead of loosing money every time you fill up at the pump… there was a way to throw the pump in reverse and fill up with cash every time you pull the handle. This "cash spout" exists in a hidden corner of the stock market. It FORCES instant payouts out of every trade. [Click here to see how it works.]() --------------------------------------------------------------- [Cincor Pharma, CINC](=) Recent Analyst Action: Dennis Ding, analyst at Jefferies, reiterates coverage on [Cincor Pharma (CINC)]()in the Healthcare sector with a Buy rating and a price target of $30 (3 weeks ago). - Recent Price: $20.44 - Average Analyst Price Target: $30.00 (46.77%) - Market Cap: $770.41M [TipRanks.com]() also reports that [Cincor Pharma]()currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $30.00. The target pricing ranges from a high forecast of $30.00 down to a low forecast of $30.00. [Cincor Pharma (CINC)]()’s last closing price was $20.44 which would put the average price target at $30.00. Here are 3rd party ratings for [CINC](): - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: n/a - Zacks.com: Hold, Top 31% (76 out of 251) [Click here for chart >>]() -------------------------------------------------------------------------- [BridgeBio Pharma, BBIO]( Recent Analyst Action: Geoff Meacham, analyst at Bank of America Securities, reiterates coverage on [BridgeBio Pharma (BBIO)](in the Healthcare sector with a Buy rating and a price target of $13 (1 week ago). - Recent Price: $11.29 - Average Analyst Price Target: $21.20 (87.78%) - Market Cap: $1.59B [TipRanks.com]() also reports that [BridgeBio Pharma]()currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $21.20. The target pricing ranges from a high forecast of $27.00 down to a low forecast of $13.00. [BridgeBio Pharma (BBIO)](’s last closing price was $11.29 which would put the average price target at $21.20. Here are 3rd party ratings for [BBIO](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 37% (91 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [The U.S. Solution to China's Copper Grab]() China consumes 54% of the world's copper. Yet China mines only 8% of its copper needs, while plundering Africa, Latin America and South America for copper. The U.S. is left scrambling for new copper sources. But there's a North American copper sweet spot overlooked by China – for now. [Find Out Where This Copper Hotspot Is and How You Can Benefit]() --------------------------------------------------------------- And there you have it--7 Five Day Gainers. Sincerely, Editor, MarketSectorDaily.com [Unsubscribe]( Sandpiper Marketing Group, LLC PO Box 407 Mt. Mourne, North Carolina 28123 United States (845) 803-0954 If you no longer wish to receive our emails, click the link below: [Unsubscribe]( Sandpiper Marketing Group, LLC PO Box 407 Mt. Mourne, North Carolina 28123 United States (845) 803-0954